Table 5.
Studies that addressed the use of postoperative radiotherapy + temozolomide in anaplastic astrocytoma
| Author | Study | Treatment arms | Histotypes | n Patients | Differences in OS | Differences in PFS | Survival Data Regarding OS in AA |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Median Survival | Actuarial survival |
|||||||||
| @1y | @2y | @4y | ||||||||
| Gilbert et al11 | Ph II | Neoadj TMZ + RT | HGG | n = 57 (AA n = 18) | – | – | 23.5 m | na | 50% | na |
| Brada et al12 | Ph II | Neoadj TMZ + RT | HGG | n = 162 (AA = 37) | – | – | 14 m | 56% | na | na |
| Chang et al13 | Ph II | Neoadj TMZ + BCNU ± RT | WHO grade III gliomas | n = 41 (AA n = 33) | – | – | na | na | ||
| Brandes et al14 | Retrosp | RT + sTMZ vs RT + PCV | AA | n = 109 (RT + TMZ n = 60) | NS | NS | na | na | 75% | na |
| na | 83% | na | ||||||||
| Combs et al15 | Retrosp | RT vs RT + cTMZ | AA + AOA (AA n = 54) | n = 60 (RT + TMZ n = 20) | NS | NS | na | na | ||
| Current study | Retrosp | RT vs RT + cTMZ + sTMZ | AA | n = 295 (RT + cTMZ + sTMZ n = 166) | NS | na | 18.1 m | 60.5% | 45.4% | 31.0% |
| 21.4 m | 75.0% | 48.1% | 27.1% | |||||||
Abbreviations: OS, overall survival; PFS, progression-free survival; Ph II, phase II study; Retrosp, retrospective study; Neoadj, neoadjuvant; TMZ, temozolomide; RT, radiotherapy; HGG, high-grade glioma; AA, anaplastic astrocytoma; BCNU, carmustine; sTMZ, sequential temozolomide; PCV, procarbazine + lomustine + vincristine; cTMZ, concomitant temozolomide; AOA, mixed anaplastic oligoastrocytoma; NS, not significant; na, not available.